Intensity Therapeutics (INTS) Other Non-Current Assets (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Other Non-Current Assets came in at $1.3 million in Q1 2026, little changed YoY from $1.3 million in Q1 2025, and little changed on a QoQ basis from $1.3 million in Q4 2025.
Intensity Therapeutics (INTS) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Other Non-Current Assets data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.15% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (changed 0.15% YoY) and the FY2025 annual result came in at $1.3 million, changed 0.15% from the prior year.
- Other Non-Current Assets steadied at $1.3 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q4 2023 to a low of $28438.0 in Q3 2023.
- A 5-year average of $1.0 million and a median of $1.3 million in 2025 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 4464.32% in 2024, down 22.92% in 2024.
- Tracing INTS's Other Non-Current Assets over 5 years: stood at $167000.0 in 2022, then jumped by 908.38% to $1.7 million in 2023, then dropped by 22.92% to $1.3 million in 2024, then decreased by 0.15% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | 210,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 210,000.00 |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Sep 30, 2023 | 28,438.00 |
| Jun 30, 2023 | 167,738.00 |
| Dec 31, 2022 | 167,000.00 |